RATIONALE: Anhedonia, or hyposensitivity to normally pleasurable stimuli, is a cardinal symptom of depression. As such, reward circuitry may comprise a substrate with relevance to this symptom of depression. OBJECTIVES: Our aim was to characterize in the rat changes in the rewarding properties of a pharmacological and a natural stimulus following olfactory bulbectomy (OBX), a pre-clinical animal model of depression. METHODS: We measured amphetamine enhancement of brain stimulation reward, changes in sucrose intake, as well as striatal cAMP response element binding protein (CREB) activity, a molecular index previously associated with depressant-like behavior. Moreover, since alteration of psychomotor activity is also a common symptom of depression, and psychostimulant reward and locomotion are thought to share common neurobiology, we used the same treatment schedule of amphetamine to probe for changes in locomotion. RESULTS: Our findings show that OBX produces a behavioral phenotype characterized by both anhedonia and exaggerated locomotor activation. Thus, we observed a blunted response to the rewarding properties of amphetamine (1 mg/kg, 21 days post-lesion), a long-lasting reduction in sucrose intake and increased striatal CREB activity. In addition, the same dose of amphetamine, at a coincident time post-lesion, triggered an exaggerated response to its locomotor-stimulant actions. CONCLUSIONS: These paradoxical findings are not consistent with the notion that reward and locomotion are mediated by a common substrate; this dissociation may be useful in modeling psychiatric disorders such as mixed depressive states. In addition, our findings suggest that central reward circuitry may constitute a possible target for rationally designed therapeutics for depression.
RATIONALE: Anhedonia, or hyposensitivity to normally pleasurable stimuli, is a cardinal symptom of depression. As such, reward circuitry may comprise a substrate with relevance to this symptom of depression. OBJECTIVES: Our aim was to characterize in the rat changes in the rewarding properties of a pharmacological and a natural stimulus following olfactory bulbectomy (OBX), a pre-clinical animal model of depression. METHODS: We measured amphetamine enhancement of brain stimulation reward, changes in sucrose intake, as well as striatal cAMP response element binding protein (CREB) activity, a molecular index previously associated with depressant-like behavior. Moreover, since alteration of psychomotor activity is also a common symptom of depression, and psychostimulant reward and locomotion are thought to share common neurobiology, we used the same treatment schedule of amphetamine to probe for changes in locomotion. RESULTS: Our findings show that OBX produces a behavioral phenotype characterized by both anhedonia and exaggerated locomotor activation. Thus, we observed a blunted response to the rewarding properties of amphetamine (1 mg/kg, 21 days post-lesion), a long-lasting reduction in sucrose intake and increased striatal CREB activity. In addition, the same dose of amphetamine, at a coincident time post-lesion, triggered an exaggerated response to its locomotor-stimulant actions. CONCLUSIONS: These paradoxical findings are not consistent with the notion that reward and locomotion are mediated by a common substrate; this dissociation may be useful in modeling psychiatric disorders such as mixed depressive states. In addition, our findings suggest that central reward circuitry may constitute a possible target for rationally designed therapeutics for depression.
Authors: Michel Barrot; Jocelien D A Olivier; Linda I Perrotti; Ralph J DiLeone; Olivier Berton; Amelia J Eisch; Soren Impey; Daniel R Storm; Rachael L Neve; Jerry C Yin; Venetia Zachariou; Eric J Nestler Journal: Proc Natl Acad Sci U S A Date: 2002-08-06 Impact factor: 11.205
Authors: W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler Journal: Science Date: 1998-12-18 Impact factor: 47.728
Authors: Philip V Holmes; Cher V Masini; Stefany D Primeaux; Joshua L Garrett; Andrew Zellner; Kimberly S Stogner; Alicia A Duncan; Jonathon D Crystal Journal: Synapse Date: 2002-10 Impact factor: 2.562
Authors: Petra Amchova; Jana Kucerova; Valentina Giugliano; Zuzana Babinska; Mary T Zanda; Maria Scherma; Ladislav Dusek; Paola Fadda; Vincenzo Micale; Alexandra Sulcova; Walter Fratta; Liana Fattore Journal: Front Pharmacol Date: 2014-03-20 Impact factor: 5.810
Authors: Yifei Jiang; Raymund Y K Pun; Katrina Peariso; Katherine D Holland; Qingquan Lian; Steve C Danzer Journal: PLoS One Date: 2015-09-14 Impact factor: 3.240
Authors: Hongyan Ren; Chiara Fabbri; Rudolf Uher; Marcella Rietschel; Ole Mors; Neven Henigsberg; Joanna Hauser; Astrid Zobel; Wolfgang Maier; Mojca Z Dernovsek; Daniel Souery; Annamaria Cattaneo; Gerome Breen; Ian W Craig; Anne E Farmer; Peter McGuffin; Cathryn M Lewis; Katherine J Aitchison Journal: Transl Psychiatry Date: 2018-08-13 Impact factor: 6.222